Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout
Evidence-Based Medicine2012Vol. 17(4), pp. 105–108
Citations Over Time
Abstract
Although febuxostat trials included allopurinol as a comparator, methodological limitations make comparative effectiveness evaluations difficult. However, when available trial data were input to a decision analytic model, the authors found that a significant reduction in febuxostat cost would be required in order for it to dominate allopurinol in cost effectiveness analysis. This case exemplifies the challenges of using clinical trial data in comparative and cost effectiveness analyses.
Related Papers
- Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.(2012)
- → Febuxostat Efficacy in Allopurinol-Resistant Tophaceous Gout(2011)4 cited
- → Risk of Severe Adverse Reactions Related to Allopurinol and Febuxostat in Asians(2018)2 cited
- [Life-threatening hyperuricemia during cytostatic leukemia therapy].(1982)
- → Comparative Study of Allopurinol and Uralyt-4 in patients with Hyperuricemia in Diyala Governorate.(2014)